Kiora Pharmaceuticals Inc
KPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001372514
No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.
Other share classesKPHMW
13F holders, Q3 2022
Institutional positions in Kiora Pharmaceuticals Inc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −5 vs. Q2 2022
- Shares held
- 34.1K
- −802.1K (−95.9%) vs. Q2 2022
- Total value
- $209.0K
- −$182.0K (−46.5%) vs. Q2 2022
- New holders
- 1
- 1 more added
- Sold out
- 6
- 7 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KPRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $2.91M |
| Q1 2026 | 18 | $654.7K |
| Q4 2025 | 19 | $1.39M |
| Q3 2025 | 17 | $1.71M |
| Q2 2025 | 16 | $2.68M |
| Q1 2025 | 18 | $3.87M |
| Q4 2024 | 16 | $4.16M |
| Q3 2024 | 19 | $5.38M |
| Q2 2024 | 17 | $5.97M |
| Q1 2024 | 24 | $7.87M |
| Q4 2023 | 15 | $159.5K |
| Q3 2023 | 14 | $91.9K |
| Q2 2023 | 18 | $425.2K |
| Q1 2023 | 14 | $283.6K |
| Q4 2022 | 11 | $518.8K |
| Q3 2022 | 9 | $209.0K |
| Q2 2022 | 14 | $391.0K |
| Q1 2022 | 16 | $517.0K |
| Q4 2021 | 13 | $1.22M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Kiora Pharmaceuticals Inc; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 14,462 | $89.0K | 0.00% | −6,519−31.1% | Reduced |
| Geode Capital Management, LLC | 14,008 | $86.0K | 0.00% | −533,120−97.4% | Reduced |
| Morgan Stanley | 2,374 | $15.0K | 0.00% | +2,041+612.9% | Added |
| UBS Group AG | 2,143 | $13.0K | 0.00% | −26,713−92.6% | Reduced |
| Spartan Fund Management Inc. | 1,000 | $6.00K | 0.00% | +1,000 | New |
| US Bancorp | 67 | $0 | 0.00% | −2,643−97.5% | Reduced |
| Wells Fargo & Company | 5 | $0 | 0.00% | −80−94.1% | Reduced |
| Albion Financial Group | 6 | $0 | 0.00% | −248−97.6% | Reduced |
| Advisor Group Holdings, Inc. | 36 | $0 | 0.00% | −1,432−97.5% | Reduced |
| Vanguard Group Inc | 0 | $0 | 0.00% | −67,212−100.0% | Sold out |
| Price T Rowe Associates Inc | 0 | $0 | 0.00% | −51,300−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −46,440−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −41,835−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −12,558−100.0% | Sold out |